Galena Biopharma (NASDAQ:GALE)‘s stock had its “hold” rating restated by stock analysts at Raymond James Financial in a note issued to investors on Monday.
Shares of Galena Biopharma (NASDAQ:GALE) opened at $0.28 on Monday. Galena Biopharma has a 12-month low of $0.26 and a 12-month high of $3.60.
A number of institutional investors have recently made changes to their positions in GALE. Renaissance Technologies LLC purchased a new stake in Galena Biopharma during the 1st quarter worth $976,000. Vaughan David Investments Inc. IL boosted its position in Galena Biopharma by 6,545.7% during the 3rd quarter. Vaughan David Investments Inc. IL now owns 864,076 shares of the biotechnology company’s stock worth $20,893,000 after purchasing an additional 851,074 shares during the period. Virtu KCG Holdings LLC boosted its position in Galena Biopharma by 677.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 195,230 shares during the period. Finally, Vanguard Group Inc. boosted its position in Galena Biopharma by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 13,302 shares during the period. 18.51% of the stock is owned by hedge funds and other institutional investors.
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.